EDP-938 + Placebo

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 17/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Respiratory Syncytial Virus Infections

Conditions

Respiratory Syncytial Virus Infections

Trial Timeline

Jul 7, 2021 → May 31, 2023

NCT ID

NCT04633187

About EDP-938 + Placebo

EDP-938 + Placebo is a phase 2 stage product being developed by Enanta Pharmaceuticals for Respiratory Syncytial Virus Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT04633187. Target conditions include Respiratory Syncytial Virus Infections.

What happened to similar drugs?

4 of 20 similar drugs in Respiratory Syncytial Virus Infections were approved

Approved (4) Terminated (1) Active (15)

🔄mRNA-1345ModernaPhase 3

✅Zopapogene imadenovec (Zopa)PrecigenApproved

✅YMC026 + PlaceboYuhanApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05568706	Phase 2	Completed	Nov 29, 2022	Jun 23, 2025	RSV Infection
NCT04816721	Phase 2	Completed	Apr 26, 2022	Aug 19, 2024	Respiratory Syncytial Virus (RSV)
NCT04633187	Phase 2	Terminated	Jul 7, 2021	May 31, 2023	Respiratory Syncytial Virus Infections
NCT04196101	Phase 2	Completed	Jan 22, 2020	Jan 4, 2022	Respiratory Syncytial Virus
NCT03384823	Phase 1	Completed	Dec 7, 2017	Jul 3, 2018	RSV Infection

Competing Products

20 competing products in Respiratory Syncytial Virus Infections

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 1	0
mRNA-1345	Moderna	Phase 2	0
mRNA-1345	Moderna	Phase 2	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Preclinical	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 1	0
Zopapogene imadenovec (Zopa)	Precigen	Approved	44
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2	Precigen	Phase 1/2	30
agenT-797	MiNK Therapeutics	Phase 1	19
YMC026 + Placebo	Yuhan	Approved	43
VN-0200 + Placebo	Daiichi Sankyo	Phase 1	29
VN-0200	Daiichi Sankyo	Phase 2	35
Isavuconazonium Injection [Cresemba] + Placebo	Astellas Pharma	Phase 3	32
S-337395 + Placebo	Shionogi	Phase 2	42
Sivelestat	Eli Lilly	Phase 1/2	32